Wave Sets October 27 Date to Review Third-Quarter Results and Update on Programs
Key Facts
Wave Life Sciences set October 27, 2026, for a conference call and webcast to review third-quarter results and provide company updates. The company said the webcast and call will begin at 8:30 a.m. Eastern time. That puts the results review the day after the stock closed at $3.21 on October 26, according to EL7 data. An earlier draft attributed revenue, per-share loss and a beat of analyst expectations to the company, but the company’s open announcement available here is limited to setting a date for the review. The confirmed news therefore concerns the expected update date, while the available evidence contains no third-quarter results figures that can be attributed to the company.
The programs Wave said it is focused on include WVE-007 for obesity, WVE-006 for alpha-1 antitrypsin deficiency and WVE-008 for PNPLA3-associated liver disease. These three areas frame the company’s expected updates, though the available announcement includes no new results for any of them. In an earlier update dated July 30, the company said dosing had begun in the multiple-dose portion of the Phase 2a INLIGHT trial of WVE-007. That portion included participants with a body mass index of 35 to 50 kg/m². On September 23, Wave announced the start of a Phase 2a combination trial pairing WVE-007 with tirzepatide for obesity.
For the WVE-006 program, Wave said on October 1 that feedback from the U.S. Food and Drug Administration supports a registration pathway for its alpha-1 antitrypsin deficiency treatment. The company also announced on September 30 that GSK had selected an siRNA therapeutic program to continue developing. These announcements place clinical program and partnership updates in the context of what the company may discuss in its third-quarter review. Previous quarterly financial results provide a reference for the earlier period: recognized revenue was $2.3 million in the second quarter of 2026, compared with $8.7 million in the same quarter of 2025. Research and development expenses were $51.3 million in the second quarter of 2026, compared with $43.5 million in the same period of 2025.
Wave said in its second-quarter results that cash, cash equivalents and marketable securities totaled $490.6 million on June 30, 2026. It added at the time that its expected funding would support operations through the third quarter of 2028. That disclosure dates to the second-quarter results published on July 30 and is not a new update on the company’s third-quarter cash position. After the results review date, the company announced that its virtual investor research day will be held on November 4, 2026. That follows the scheduled update on October 27 and provides a later date for presenting the company’s research programs.